The 2016 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of colorectal cancer, prostate cancer, distress management, CML, ovarian cancer, and multiple myeloma.

Join Richard Penson, MD and Laura Sullivan, RN from Massachusetts General Hospital Cancer Center as they present their expertise on a range of cases pertaining to ovarian cancer.

Join Richard Penson, MD and Laura Sullivan, RN from Massachusetts General Hospital Cancer Center as they present their expertise on a range of cases pertaining to ovarian cancer.

Borderline ovarian tumors (BOTs) are less common than epithelial ovarian cancers (EOCs). Low-grade EOCs (LG-EOCs) occur even less frequently than BOTs.

This information was originally presented at the NCCN 21^st Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida, from March 31 – April 2, 2016.

Objective: To identify risk factors associated with refusal of recommended chemotherapy and its impact on patients with epithelial ovarian cancer (EOC).

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes.

The goal of this activity is to improve participants’ competence in providing optimal care for patients with ovarian and cervical cancer as well as their knowledge of emerging clinical trial data and current guideline and expert recommendations.

The goal of this activity is to improve participants’ competence in providing optimal care for patients with ovarian and cervical cancer as well as their knowledge of emerging clinical trial data and current guideline and expert recommendations.

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials.